{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:49:41Z","timestamp":1740134981273,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"FP7 NGS-PTL","award":["306242"],"award-info":[{"award-number":["306242"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3511-2","type":"journal-article","created":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T08:17:52Z","timestamp":1501921072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4315-5996","authenticated-orcid":false,"given":"Caterina","family":"De Benedittis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Venturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Abbenante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,5]]},"reference":[{"issue":"3","key":"3511_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3324\/haematol.2015.124016","volume":"100","author":"V Leoni","year":"2015","unstructured":"Leoni V, Biondi A. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):295\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"3511_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2012.708753","volume":"54","author":"JM Ribera","year":"2013","unstructured":"Ribera JM. Optimal approach to treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia: how to best use all the available tools. Leuk Lymphoma. 2013;54(1):21\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3511_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11899-013-0155-4","volume":"8","author":"AK Fielding","year":"2013","unstructured":"Fielding AK, Zakout GA. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013;8(2):98\u2013108.","journal-title":"Curr Hematol Malig Rep"},{"issue":"24","key":"3511_CR4","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3511_CR5","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002\u20139.","journal-title":"Cancer"},{"issue":"3","key":"3511_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007;92(3):401\u20134.","journal-title":"Haematologica"},{"issue":"22","key":"3511_CR7","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075\u201388.","journal-title":"N Engl J Med"},{"issue":"3","key":"3511_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428\u201342.","journal-title":"Cancer Cell"},{"key":"3511_CR9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2147\/OTT.S70524","volume":"8","author":"JM Ribera","year":"2015","unstructured":"Ribera JM, Ferrer A, Ribera J, Genesca E. Profile of blinatumomab and its potential in the treatment of relapsed\/refractory acute lymphoblastic leukemia. Onco Targets Ther. 2015;8:1567\u201374.","journal-title":"Onco Targets Ther"},{"key":"3511_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Jiaping F. Mingzhi Zhang and Delong Liu. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104. doi:\n10.1186\/s13045-015-0195-4\n\n.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"3511_CR11","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"S Soverini","year":"2013","unstructured":"Soverini S, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634\u201348.","journal-title":"Blood"},{"key":"3511_CR12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000063562","volume":"59","author":"HH Zakon","year":"2002","unstructured":"Zakon HH. Convergent Evolution on the Molecular Level. Brain Behav Evol. 2002;59:250\u201361.","journal-title":"Brain Behav Evol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3511-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,5]],"date-time":"2017-08-05T08:17:59Z","timestamp":1501921079000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3511-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,5]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3511-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2017,8,5]]},"article-number":"523"}}